Caricamento...
The Three P's: Parotid, PD-L1, and Pembrolizumab
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
Salvato in:
| Pubblicato in: | Case Rep Oncol Med |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Hindawi
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594310/ https://ncbi.nlm.nih.gov/pubmed/31308983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/2305315 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|